Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
Overview
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Indication
For the treatment of cancer and bone marrow transplant
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Hematopoietic Subsyndrome of Acute Radiation Syndrome
- Hodgkin's Lymphoma
- Neutropenia
- Non-Hodgkin's Lymphoma (NHL)
- Severe Infection
Clinical Trials
FDA Approved Products
Leukine
Manufacturer:Partner Therapeutics, Inc.
Route:SUBCUTANEOUS, INTRAVENOUS
Strength:250 ug in 1 mL
Approved: 2023/08/31
NDC:71837-5843
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath